TY - JOUR
T1 - Concurrent positive anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase antibody with reducing body myopathy
T2 - Possible double trouble
AU - Tanboon, Jantima
AU - Sanmaneechai, Oranee
AU - Charuvanij, Sirirat
AU - Sangruchi, Tumtip
AU - Galindo-Feria, Angeles S.
AU - Lundberg, Ingrid E.
AU - Ohnuki, Yuko
AU - Shiina, Takashi
AU - Suzuki, Shigeaki
AU - Nishino, Ichizo
N1 - Funding Information:
This study was supported partly by Intramural Research Grant (29–4) for Neurological and Psychiatric Disorders of NCNP, and AMED under Grant Numbers JP19ek0109285h0003 and JP18kk0205001s0203.
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/7
Y1 - 2019/7
N2 - Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase myopathy is less common in children but has been associated with more favorable prognosis than adult patients after immunotherapies. We report anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody positivity in a 6-year-old boy with progressive muscle weakness, scoliosis, spinal rigidity, multiple joint contractures, mild left ventricular hypertrophy, and elevated serum creatine kinase. In contrast to most of previously reported pediatric anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase myopathy, he showed little response to immunotherapies. Muscle biopsy contained changes suggestive of myofiber necrosis and regeneration and reducing bodies. The diagnosis of reducing body myopathy was later confirmed by reported c.368A>G (p.His123Arg) mutation in the FHL1 gene. Although the level of association between these two conditions is still inconclusive, this is the first report of concurrent positive anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody with reducing body myopathy emphasizing the possibility of co-occurrence of immune mediated necrotizing myopathy and muscular dystrophy and importance of comprehensive diagnostic investigations in unusual cases.
AB - Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase myopathy is less common in children but has been associated with more favorable prognosis than adult patients after immunotherapies. We report anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody positivity in a 6-year-old boy with progressive muscle weakness, scoliosis, spinal rigidity, multiple joint contractures, mild left ventricular hypertrophy, and elevated serum creatine kinase. In contrast to most of previously reported pediatric anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase myopathy, he showed little response to immunotherapies. Muscle biopsy contained changes suggestive of myofiber necrosis and regeneration and reducing bodies. The diagnosis of reducing body myopathy was later confirmed by reported c.368A>G (p.His123Arg) mutation in the FHL1 gene. Although the level of association between these two conditions is still inconclusive, this is the first report of concurrent positive anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody with reducing body myopathy emphasizing the possibility of co-occurrence of immune mediated necrotizing myopathy and muscular dystrophy and importance of comprehensive diagnostic investigations in unusual cases.
KW - 3-hydroxy-3-methylglutaryl-coenzyme A reductase
KW - FHL1
KW - HMGCR
KW - IMNM
KW - Immune mediated necrotizing myopathy
KW - Reducing body myopathy
UR - http://www.scopus.com/inward/record.url?scp=85067210853&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067210853&partnerID=8YFLogxK
U2 - 10.1016/j.nmd.2019.05.007
DO - 10.1016/j.nmd.2019.05.007
M3 - Article
C2 - 31204143
AN - SCOPUS:85067210853
SN - 0960-8966
VL - 29
SP - 543
EP - 548
JO - Neuromuscular Disorders
JF - Neuromuscular Disorders
IS - 7
ER -